Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

Innovative Trials

- PMLiVE

VarmX and CSL to collaborate in research deal worth up to $2.1bn

VarmX's lead candidate, VMX-C001, recently received US FDA Fast Track Designation

- PMLiVE

Graphene Medical Animation launches

New studio led by EMMY- and BAFTA-winning talent delivers cinematic medical animation for pharma, biotech and med comms

- PMLiVE

Lucid Strategy Consulting: Empowering Next-Generation Solutions for Life Sciences

Lucid Group announces the evolution of its consulting division, Lucid Strategy Consulting, setting a new standard for deep-domain, knowledge-led consulting solutions for life sciences. We have brought together two Lucid...

Lucid Group Communications Limited

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

PMi Awards 2025

Winners included Camino Communications and Jazz Pharmaceuticals

Streamlining European expansion for cell and gene therapies

Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...

Uniphar

- PMLiVE

Current CGT landscape and future outlook  

What makes CGT unique  Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...

Uniphar

- PMLiVE

Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals 

This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...

Uniphar

- PMLiVE

Navigating the complexities of launch preparation for Cell and Gene Therapy

Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...

Uniphar

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

Virtual Practice, Real Results: The Power of Virtual Patient Simulation

Simulation has never been more vital in medicine than it is today. As increasing numbers of physicians turn to large language models for clinical answers1, the real differentiator isn’t just...

Medscape Education

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links